Company Profile

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

Employees

Sector

Biotechnology & Medical Research

More about the company

04/12	Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026	CI
06/24/06	ArQule, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
16/20/16	ArQule, Inc. Announces Management Changes	CI
16/20/16	ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P TMI Index	CI
16/20/16	ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Biotechnology Select Industry Index	CI
16/20/16	ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Global BMI Index	CI
15/20/15	Merck Sharp & Dohme Corp. completed the acquisition of ArQule, Inc..	CI
10/19/10	Wall St. falls as Apple, health shares drag, tariff deadline looms	RE
09/19/09	ArQule, Inc. - Special Call
09/19/09	ArQule, Inc. Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	CI
09/19/09	Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire ArQule, Inc. for $2.4 billion.	CI
25/19/25	ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	CI
06/19/06	ArQule, Inc. Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies	CI

13/20/13	ArQule : Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors	AQ
14/20/14	Merck : KEYTRUDA Superior to Brentuximab Vedotin, a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial	AQ
16/20/16	ARQULE INC : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
17/19/17	ARQULE INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
10/19/10	Fate Therapeutics : ArQule and Fate Therapeutics soar; Sanofi and Diplomat fall	AQ

10/19/10	NASDAQ COMPOSITE : Wall Street finit en baisse à l'approche d'une échéance clé pour le commerce
09/19/09	DOW JONES 30 : Wall Street ouvre en légère baisse
09/19/09	ArQule : Merck & Co verstärkt sich für 2,7 Mrd Dollar in der Krebsmedizin
09/19/09	US-Pharmakonzern Merck & Co will Krebsspezialisten Arqule übernehmen
09/19/09	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Dalton Smart PSD	President	60	-
Aaron Rosenberg TRE	Treasurer	50	-
Jonathan Filderman PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Jonathan Filderman BRD	Director/Board Member	-	-
Dalton Smart BRD	Director/Board Member	60	-
Aaron Rosenberg BRD	Director/Board Member	50	-

ArQule, Inc. Share Price

Stocks

US04269E1073

Biotechnology & Medical Research

Latest news : ArQule, Inc.

Press Releases: ArQule, Inc.

News in other languages: ArQule, Inc.

Managers and Directors: ArQule, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/01/20	William G. Messenger	Tender	Director	2,10,000	0.1739%
16/01/20	Marc Schegerin	Tender	CFO and Treasurer	5,21,001	0.4313%
16/01/20	Ronald M. Lindsay	Tender	Director	2,50,800	0.2076%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARQULE, INC.	-.--%	-0.10%	-	-	241.75Cr
LONZA GROUP AG	-1.53%	+0.82%	+3.66%	+14.53%	4.95TCr
REVOLUTION MEDICINES, INC.	-0.69%	+6.25%	+492.36%	+585.40%	4.41TCr
BEONE MEDICINES AG	+0.08%	+11.23%	+23.99%	+81.74%	4.08TCr
IQVIA HOLDINGS INC.	+0.76%	+6.85%	+35.40%	+10.92%	4.01TCr
CELLTRION, INC.	+4.73%	+13.29%	+27.76%	+54.22%	3.42TCr
MEDPACE HOLDINGS, INC.	+0.51%	+5.29%	+34.62%	+126.87%	1.69TCr
ASCENDIS PHARMA A/S	-0.41%	+4.08%	-	-	1.68TCr
EUROFINS SCIENTIFIC SE	-0.49%	-0.23%	+4.10%	+20.57%	1.4TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.81%	+20.45%	+89.35%	+31.49%	1.35TCr
Average	+0.45%	+7.75%	+88.91%	+115.72%	3TCr
Weighted average by Cap.	+0.36%	+7.39%	+106.94%	+138.26%